Comparing SG&A Expenses: Merck & Co., Inc. vs Evotec SE Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Over the past decade, Merck & Co., Inc. and Evotec SE have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses.

Merck & Co., Inc.: A Steady Giant

From 2014 to 2023, Merck's SG&A expenses have remained relatively stable, averaging around $10 billion annually. Despite minor fluctuations, Merck's financial discipline reflects its robust market position and strategic investments in R&D and marketing.

Evotec SE: A Rising Star

In contrast, Evotec SE has experienced a dramatic increase in SG&A expenses, growing by over 800% from 2014 to 2023. This surge underscores Evotec's aggressive expansion and investment in innovation, positioning it as a formidable player in the biotech sector.

These trends highlight the diverse strategies employed by pharmaceutical companies to navigate market challenges and opportunities.